JP2008512486A - 有機化合物の組み合わせ - Google Patents

Info

Publication number

JP2008512486A

JP2008512486A JP2007531384A JP2007531384A JP2008512486A JP 2008512486 A JP2008512486 A JP 2008512486A JP 2007531384 A JP2007531384 A JP 2007531384A JP 2007531384 A JP2007531384 A JP 2007531384A JP 2008512486 A JP2008512486 A JP 2008512486A

Authority

JP

Japan

Prior art keywords

phenyl

disease

inhibitor

pharmaceutically acceptable

methyl

Prior art date

2004-09-09

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 150000002894 organic compounds Chemical class 0.000 title 1
• 150000001875 compounds Chemical class 0.000 claims abstract description 75
• 150000003839 salts Chemical class 0.000 claims abstract description 53
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 29
• 239000003112 inhibitor Substances 0.000 claims abstract description 24
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
• 239000002461 renin inhibitor Substances 0.000 claims abstract description 16
• 229940086526 renin-inhibitors Drugs 0.000 claims abstract description 16
• 239000003472 antidiabetic agent Substances 0.000 claims abstract description 13
• 201000010099 disease Diseases 0.000 claims abstract description 12
• 238000011282 treatment Methods 0.000 claims abstract description 11
• 239000004480 active ingredient Substances 0.000 claims abstract description 10
• 239000002220 antihypertensive agent Substances 0.000 claims abstract description 10
• PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims abstract description 9
• PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims abstract description 9
• 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 9
• 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 9
• 229940126033 PPAR agonist Drugs 0.000 claims abstract description 9
• 229940122388 Thrombin inhibitor Drugs 0.000 claims abstract description 9
• 229960002478 aldosterone Drugs 0.000 claims abstract description 9
• 239000005557 antagonist Substances 0.000 claims abstract description 9
• 229940127088 antihypertensive drug Drugs 0.000 claims abstract description 9
• 230000001906 cholesterol absorption Effects 0.000 claims abstract description 9
• 230000001965 increasing effect Effects 0.000 claims abstract description 9
• 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims abstract description 9
• 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 claims abstract description 9
• 208000010110 spontaneous platelet aggregation Diseases 0.000 claims abstract description 9
• 239000003868 thrombin inhibitor Substances 0.000 claims abstract description 9
• 108010059886 Apolipoprotein A-I Proteins 0.000 claims abstract description 8
• 102000005666 Apolipoprotein A-I Human genes 0.000 claims abstract description 8
• 102100033868 Cannabinoid receptor 1 Human genes 0.000 claims abstract description 8
• 101710187010 Cannabinoid receptor 1 Proteins 0.000 claims abstract description 8
• 229940122904 Glucagon receptor antagonist Drugs 0.000 claims abstract description 8
• 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims abstract description 8
• 229940127003 anti-diabetic drug Drugs 0.000 claims abstract description 8
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 8
• 206010020772 Hypertension Diseases 0.000 claims abstract description 7
• 239000000883 anti-obesity agent Substances 0.000 claims abstract description 7
• 229940125710 antiobesity agent Drugs 0.000 claims abstract description 7
• 239000003937 drug carrier Substances 0.000 claims abstract description 7
• 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims abstract description 7
• 206010019280 Heart failures Diseases 0.000 claims abstract description 6
• 208000008589 Obesity Diseases 0.000 claims abstract description 6
• 208000002551 irritable bowel syndrome Diseases 0.000 claims abstract description 6
• 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims abstract description 6
• 235000020824 obesity Nutrition 0.000 claims abstract description 6
• 230000005586 smoking cessation Effects 0.000 claims abstract description 6
• 208000002705 Glucose Intolerance Diseases 0.000 claims abstract description 5
• 201000009104 prediabetes syndrome Diseases 0.000 claims abstract description 5
• 230000002265 prevention Effects 0.000 claims abstract description 5
• 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 4
• 208000006011 Stroke Diseases 0.000 claims abstract description 4
• 201000001421 hyperglycemia Diseases 0.000 claims abstract description 4
• 208000006575 hypertriglyceridemia Diseases 0.000 claims abstract description 4
• 208000010125 myocardial infarction Diseases 0.000 claims abstract description 4
• 208000037803 restenosis Diseases 0.000 claims abstract description 4
• 230000000391 smoking effect Effects 0.000 claims abstract description 4
• 208000011580 syndromic disease Diseases 0.000 claims abstract description 4
• 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 3
• 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 3
• 206010006187 Breast cancer Diseases 0.000 claims abstract description 3
• 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 3
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 3
• 206010009900 Colitis ulcerative Diseases 0.000 claims abstract description 3
• 206010009944 Colon cancer Diseases 0.000 claims abstract description 3
• 208000011231 Crohn disease Diseases 0.000 claims abstract description 3
• 208000032928 Dyslipidaemia Diseases 0.000 claims abstract description 3
• 206010014950 Eosinophilia Diseases 0.000 claims abstract description 3
• 208000018522 Gastrointestinal disease Diseases 0.000 claims abstract description 3
• 208000035150 Hypercholesterolemia Diseases 0.000 claims abstract description 3
• 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 3
• 206010061218 Inflammation Diseases 0.000 claims abstract description 3
• 206010022562 Intermittent claudication Diseases 0.000 claims abstract description 3
• 208000017170 Lipid metabolism disease Diseases 0.000 claims abstract description 3
• 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract description 3
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 3
• 206010060862 Prostate cancer Diseases 0.000 claims abstract description 3
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 3
• 208000001647 Renal Insufficiency Diseases 0.000 claims abstract description 3
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims abstract description 3
• 201000006704 Ulcerative Colitis Diseases 0.000 claims abstract description 3
• 201000004810 Vascular dementia Diseases 0.000 claims abstract description 3
• 208000026935 allergic disease Diseases 0.000 claims abstract description 3
• 239000000427 antigen Substances 0.000 claims abstract description 3
• 102000036639 antigens Human genes 0.000 claims abstract description 3
• 108091007433 antigens Proteins 0.000 claims abstract description 3
• 206010003246 arthritis Diseases 0.000 claims abstract description 3
• 208000006673 asthma Diseases 0.000 claims abstract description 3
• 201000011510 cancer Diseases 0.000 claims abstract description 3
• 230000000747 cardiac effect Effects 0.000 claims abstract description 3
• 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 3
• 208000030533 eye disease Diseases 0.000 claims abstract description 3
• 230000009610 hypersensitivity Effects 0.000 claims abstract description 3
• 230000002757 inflammatory effect Effects 0.000 claims abstract description 3
• 230000004054 inflammatory process Effects 0.000 claims abstract description 3
• 230000028709 inflammatory response Effects 0.000 claims abstract description 3
• 208000021156 intermittent vascular claudication Diseases 0.000 claims abstract description 3
• 201000006370 kidney failure Diseases 0.000 claims abstract description 3
• 230000004060 metabolic process Effects 0.000 claims abstract description 3
• 201000001474 proteinuria Diseases 0.000 claims abstract description 3
• 208000023504 respiratory system disease Diseases 0.000 claims abstract description 3
• 208000017520 skin disease Diseases 0.000 claims abstract description 3
• 239000000779 smoke Substances 0.000 claims abstract description 3
• 201000005665 thrombophilia Diseases 0.000 claims abstract description 3
• 230000003247 decreasing effect Effects 0.000 claims abstract 2
• 239000000556 agonist Substances 0.000 claims description 13
• 208000035475 disorder Diseases 0.000 claims description 11
• 238000000034 method Methods 0.000 claims description 11
• 239000005541 ACE inhibitor Substances 0.000 claims description 8
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 8
• 239000002876 beta blocker Substances 0.000 claims description 8
• 229940097320 beta blocking agent Drugs 0.000 claims description 7
• 206010012601 diabetes mellitus Diseases 0.000 claims description 6
• 230000009977 dual effect Effects 0.000 claims description 6
• 208000030159 metabolic disease Diseases 0.000 claims description 6
• 229940127291 Calcium channel antagonist Drugs 0.000 claims description 5
• 239000000480 calcium channel blocker Substances 0.000 claims description 5
• 241001465754 Metazoa Species 0.000 claims description 4
• 229940124754 PPAR-alpha/gamma agonist Drugs 0.000 claims description 4
• 239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 4
• 239000002934 diuretic Substances 0.000 claims description 4
• 230000001882 diuretic effect Effects 0.000 claims description 4
• NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 claims description 3
• 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims description 3
• 206010057852 Nicotine dependence Diseases 0.000 claims description 3
• 108010028924 PPAR alpha Proteins 0.000 claims description 3
• 102000023984 PPAR alpha Human genes 0.000 claims description 3
• GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims description 3
• 239000003623 enhancer Substances 0.000 claims description 3
• 208000019553 vascular disease Diseases 0.000 claims description 3
• ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical group C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 claims description 3
• 229960001522 ximelagatran Drugs 0.000 claims description 3
• 206010054196 Affect lability Diseases 0.000 claims description 2
• 208000019901 Anxiety disease Diseases 0.000 claims description 2
• 208000022497 Cocaine-Related disease Diseases 0.000 claims description 2
• 201000004681 Psoriasis Diseases 0.000 claims description 2
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 2
• 208000025569 Tobacco Use disease Diseases 0.000 claims description 2
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
• 229940125708 antidiabetic agent Drugs 0.000 claims description 2
• 230000036506 anxiety Effects 0.000 claims description 2
• 201000006145 cocaine dependence Diseases 0.000 claims description 2
• 208000016097 disease of metabolism Diseases 0.000 claims description 2
• 206010013663 drug dependence Diseases 0.000 claims description 2
• 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
• OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical group N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims description 2
• 206010021654 increased appetite Diseases 0.000 claims description 2
• 206010022437 insomnia Diseases 0.000 claims description 2
• 230000002503 metabolic effect Effects 0.000 claims description 2
• 229940020573 plavix Drugs 0.000 claims description 2
• 229940051223 zetia Drugs 0.000 claims description 2
• NMTKJEZOWHRAQY-UHFFFAOYSA-N 8-[(6-methoxyisoquinolin-4-yl)methyl]-1-methyl-3-(2-methylpropyl)-7h-purine-2,6-dione Chemical group CC(C)CN1C(=O)N(C)C(=O)C(N2)=C1N=C2CC1=CN=CC2=CC=C(OC)C=C21 NMTKJEZOWHRAQY-UHFFFAOYSA-N 0.000 claims 1
• 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims 1
• 208000027418 Wounds and injury Diseases 0.000 claims 1
• 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 claims 1
• 229940030600 antihypertensive agent Drugs 0.000 claims 1
• 230000005961 cardioprotection Effects 0.000 claims 1
• 230000006378 damage Effects 0.000 claims 1
• 208000014674 injury Diseases 0.000 claims 1
• 208000028867 ischemia Diseases 0.000 claims 1
• 230000001737 promoting effect Effects 0.000 claims 1
• 241000124008 Mammalia Species 0.000 abstract description 3
• 229940126904 hypoglycaemic agent Drugs 0.000 abstract description 3
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract description 2
• 206010063837 Reperfusion injury Diseases 0.000 abstract description 2
• 208000012947 ischemia reperfusion injury Diseases 0.000 abstract description 2
• 229960002715 nicotine Drugs 0.000 abstract description 2
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract description 2
• 238000002054 transplantation Methods 0.000 abstract description 2
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
• 206010063409 Acarodermatitis Diseases 0.000 abstract 1
• 206010012335 Dependence Diseases 0.000 abstract 1
• 241000447727 Scabies Species 0.000 abstract 1
• 210000004204 blood vessel Anatomy 0.000 abstract 1
• 229960003920 cocaine Drugs 0.000 abstract 1
• 230000020764 fibrinolysis Effects 0.000 abstract 1
• 208000005687 scabies Diseases 0.000 abstract 1
• 229910052739 hydrogen Inorganic materials 0.000 description 56
• 239000001257 hydrogen Substances 0.000 description 56
• 230000003287 optical effect Effects 0.000 description 35
• 125000000217 alkyl group Chemical group 0.000 description 34
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 31
• 229910052760 oxygen Inorganic materials 0.000 description 23
• 229910052717 sulfur Inorganic materials 0.000 description 23
• -1 aralkoxy Chemical group 0.000 description 22
• 125000003545 alkoxy group Chemical group 0.000 description 21
• 150000002431 hydrogen Chemical class 0.000 description 21
• 239000000203 mixture Substances 0.000 description 21
• 125000003710 aryl alkyl group Chemical group 0.000 description 17
• 125000005843 halogen group Chemical group 0.000 description 17
• 125000003118 aryl group Chemical group 0.000 description 16
• 125000000547 substituted alkyl group Chemical group 0.000 description 15
• 125000004432 carbon atom Chemical group C* 0.000 description 12
• 125000000753 cycloalkyl group Chemical group 0.000 description 12
• 125000001072 heteroaryl group Chemical group 0.000 description 12
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 11
• 230000000694 effects Effects 0.000 description 10
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 10
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 9
• 150000003254 radicals Chemical class 0.000 description 9
• 125000004475 heteroaralkyl group Chemical group 0.000 description 8
• YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 7
• 229940079593 drug Drugs 0.000 description 7
• 239000003814 drug Substances 0.000 description 7
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 7
• 125000004093 cyano group Chemical group *C#N 0.000 description 6
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
• 229910052757 nitrogen Inorganic materials 0.000 description 6
• 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 5
• YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 5
• 229910052736 halogen Inorganic materials 0.000 description 5
• 150000002367 halogens Chemical class 0.000 description 5
• 125000000623 heterocyclic group Chemical group 0.000 description 5
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 5
• HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 5
• 238000012360 testing method Methods 0.000 description 5
• 230000001225 therapeutic effect Effects 0.000 description 5
• SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 4
• 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 4
• 102000003729 Neprilysin Human genes 0.000 description 4
• 108090000028 Neprilysin Proteins 0.000 description 4
• 239000013543 active substance Substances 0.000 description 4
• 125000002947 alkylene group Chemical group 0.000 description 4
• 230000009286 beneficial effect Effects 0.000 description 4
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
• 229940002612 prodrug Drugs 0.000 description 4
• 239000000651 prodrug Substances 0.000 description 4
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
• 229960001722 verapamil Drugs 0.000 description 4
• 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 description 3
• 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 3
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
• XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 3
• 206010007559 Cardiac failure congestive Diseases 0.000 description 3
• JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 3
• 108010061435 Enalapril Proteins 0.000 description 3
• 102100040134 Free fatty acid receptor 4 Human genes 0.000 description 3
• 101710142055 Free fatty acid receptor 4 Proteins 0.000 description 3
• 108010063919 Glucagon Receptors Proteins 0.000 description 3
• 102100040890 Glucagon receptor Human genes 0.000 description 3
• DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 3
• 108010015181 PPAR delta Proteins 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 229960000528 amlodipine Drugs 0.000 description 3
• HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 3
• 239000000074 antisense oligonucleotide Substances 0.000 description 3
• 238000012230 antisense oligonucleotides Methods 0.000 description 3
• 229960004530 benazepril Drugs 0.000 description 3
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
• 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 3
• HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 3
• 229960004166 diltiazem Drugs 0.000 description 3
• 229960000873 enalapril Drugs 0.000 description 3
• GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 3
• 125000004433 nitrogen atom Chemical group N* 0.000 description 3
• 230000000144 pharmacologic effect Effects 0.000 description 3
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
• 108090000623 proteins and genes Proteins 0.000 description 3
• 230000003637 steroidlike Effects 0.000 description 3
• 230000002195 synergetic effect Effects 0.000 description 3
• 230000002792 vascular Effects 0.000 description 3
• HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 2
• MYHMSPXTUIKVGN-OAQYLSRUSA-N (2r)-1-[2-[4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1COC(C=C1)=CC=C1CC(=O)N1CCC[C@@H]1C(O)=O MYHMSPXTUIKVGN-OAQYLSRUSA-N 0.000 description 2
• BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 2
• UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
• 229930182837 (R)-adrenaline Natural products 0.000 description 2
• PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 2
• DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 2
• ZCTDTVUDURCGFX-UHFFFAOYSA-N 3-[(2-benzyl-3-sulfanylpropanoyl)amino]propanoic acid Chemical compound OC(=O)CCNC(=O)C(CS)CC1=CC=CC=C1 ZCTDTVUDURCGFX-UHFFFAOYSA-N 0.000 description 2
• UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 2
• CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 2
• 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 2
• NFFXEUUOMTXWCX-UHFFFAOYSA-N 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-n-[[4-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound C1=C(C(=O)NCC=2C=CC(=CC=2)C(F)(F)F)C(OC)=CC=C1CC1SC(=O)NC1=O NFFXEUUOMTXWCX-UHFFFAOYSA-N 0.000 description 2
• ITLAZBMGSXRIEF-UHFFFAOYSA-N 5-naphthalen-2-ylsulfonyl-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1S(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 ITLAZBMGSXRIEF-UHFFFAOYSA-N 0.000 description 2
• 239000004072 C09CA03 - Valsartan Substances 0.000 description 2
• 206010048554 Endothelial dysfunction Diseases 0.000 description 2
• 108010011459 Exenatide Proteins 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 2
• 108010016731 PPAR gamma Proteins 0.000 description 2
• 102000000536 PPAR gamma Human genes 0.000 description 2
• 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
• 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
• 102000001708 Protein Isoforms Human genes 0.000 description 2
• 108010029485 Protein Isoforms Proteins 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• 125000004414 alkyl thio group Chemical group 0.000 description 2
• 230000000692 anti-sense effect Effects 0.000 description 2
• 239000003886 aromatase inhibitor Substances 0.000 description 2
• 125000004659 aryl alkyl thio group Chemical group 0.000 description 2
• 125000005110 aryl thio group Chemical group 0.000 description 2
• 125000004104 aryloxy group Chemical group 0.000 description 2
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
• 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
• UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
• 229940000635 beta-alanine Drugs 0.000 description 2
• 125000002619 bicyclic group Chemical group 0.000 description 2
• 230000015572 biosynthetic process Effects 0.000 description 2
• 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
• 229960000830 captopril Drugs 0.000 description 2
• FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 150000001721 carbon Chemical group 0.000 description 2
• 238000011260 co-administration Methods 0.000 description 2
• 208000029078 coronary artery disease Diseases 0.000 description 2
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
• 230000008694 endothelial dysfunction Effects 0.000 description 2
• 229960005139 epinephrine Drugs 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• ZVQXPUMRSJGLSF-ZVAWYAOSSA-N ethyl (2s)-2-[[2-(acetylsulfanylmethyl)-3-(2-methylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound CCOC(=O)[C@H](CCSC)NC(=O)C(CSC(C)=O)CC1=CC=CC=C1C ZVQXPUMRSJGLSF-ZVAWYAOSSA-N 0.000 description 2
• 229960001519 exenatide Drugs 0.000 description 2
• 229950011548 fadrozole Drugs 0.000 description 2
• 229960002490 fosinopril Drugs 0.000 description 2
• 206010061989 glomerulosclerosis Diseases 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 125000005842 heteroatom Chemical group 0.000 description 2
• 229960002003 hydrochlorothiazide Drugs 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 229960004427 isradipine Drugs 0.000 description 2
• VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 2
• 229960002237 metoprolol Drugs 0.000 description 2
• IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
• FTRMOJIRMFXZJV-UHFFFAOYSA-N n-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenyl]-1-phenylcyclopropane-1-carboxamide Chemical compound C1CC1(C=1C=CC=CC=1)C(=O)NC(C=C1)=CC=C1CC1SC(=O)NC1=O FTRMOJIRMFXZJV-UHFFFAOYSA-N 0.000 description 2
• 229960001783 nicardipine Drugs 0.000 description 2
• HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
• 229960001597 nifedipine Drugs 0.000 description 2
• 229960000715 nimodipine Drugs 0.000 description 2
• 229960000227 nisoldipine Drugs 0.000 description 2
• 229960005425 nitrendipine Drugs 0.000 description 2
• 125000004043 oxo group Chemical group O=* 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 229960002582 perindopril Drugs 0.000 description 2
• IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 2
• 239000000825 pharmaceutical preparation Substances 0.000 description 2
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
• 229960005095 pioglitazone Drugs 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
• 229960003712 propranolol Drugs 0.000 description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 229960003401 ramipril Drugs 0.000 description 2
• HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 2
• 229960004586 rosiglitazone Drugs 0.000 description 2
• 239000012453 solvate Substances 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 239000011593 sulfur Chemical group 0.000 description 2
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
• RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 2
• 229960001641 troglitazone Drugs 0.000 description 2
• GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 2
• CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 1
• FELURRGTDWWQSQ-OAQYLSRUSA-N (2r)-1-[2-[3-[(1-benzyl-4-ethyl-5-oxo-1,2,4-triazol-3-yl)methoxy]phenyl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound N=1N(CC=2C=CC=CC=2)C(=O)N(CC)C=1COC(C=1)=CC=CC=1CC(=O)N1CCC[C@@H]1C(O)=O FELURRGTDWWQSQ-OAQYLSRUSA-N 0.000 description 1
• OOMSUFVRQPKSIS-LJQANCHMSA-N (2r)-1-[2-[3-[(4-methylphenyl)methoxy]phenyl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C1=CC(C)=CC=C1COC1=CC=CC(CC(=O)N2[C@H](CCC2)C(O)=O)=C1 OOMSUFVRQPKSIS-LJQANCHMSA-N 0.000 description 1
• GKSZYJFJGGPJEY-OAQYLSRUSA-N (2r)-1-[2-[3-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1COC(C=1)=CC=CC=1CC(=O)N1CCC[C@@H]1C(O)=O GKSZYJFJGGPJEY-OAQYLSRUSA-N 0.000 description 1
• AXJRSRRSVKNLRF-JOCHJYFZSA-N (2r)-1-[2-[3-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCOC(C=1)=CC=CC=1CC(=O)N1CCC[C@@H]1C(O)=O AXJRSRRSVKNLRF-JOCHJYFZSA-N 0.000 description 1
• JZXKBUXSMPRHKH-JOCHJYFZSA-N (2r)-1-[2-[3-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethyl]phenyl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCC(C=1)=CC=CC=1CC(=O)N1CCC[C@@H]1C(O)=O JZXKBUXSMPRHKH-JOCHJYFZSA-N 0.000 description 1
• KIABGZUYZPWMSG-HXUWFJFHSA-N (2r)-1-[2-[3-[[(4-methyl-2-phenyl-1,3-thiazole-5-carbonyl)amino]methyl]phenyl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound CC=1N=C(C=2C=CC=CC=2)SC=1C(=O)NCC(C=1)=CC=CC=1CC(=O)N1CCC[C@@H]1C(O)=O KIABGZUYZPWMSG-HXUWFJFHSA-N 0.000 description 1
• DTIYJFNHXCIKNF-HXUWFJFHSA-N (2r)-1-[2-[3-[[(4-methyl-5-phenyl-1,3-thiazole-2-carbonyl)amino]methyl]phenyl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound CC=1N=C(C(=O)NCC=2C=C(CC(=O)N3[C@H](CCC3)C(O)=O)C=CC=2)SC=1C1=CC=CC=C1 DTIYJFNHXCIKNF-HXUWFJFHSA-N 0.000 description 1
• HXCUYKOERLYCQK-AREMUKBSSA-N (2r)-1-[2-[3-[[2-(4-carbamoylphenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]-2,3-dihydroindole-2-carboxylic acid Chemical compound N=1C(COC=2C=C(C=CC=2)C(C)(C)C(=O)N2C3=CC=CC=C3C[C@@H]2C(O)=O)=C(C)OC=1C1=CC=C(C(N)=O)C=C1 HXCUYKOERLYCQK-AREMUKBSSA-N 0.000 description 1
• MEGNCBZSEWJJOV-JOCHJYFZSA-N (2r)-1-[2-[3-[[2-(4-carbamoylphenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC=1OC(C=2C=CC(=CC=2)C(N)=O)=NC=1COC(C=1)=CC=CC=1C(C)(C)C(=O)N1CCC[C@@H]1C(O)=O MEGNCBZSEWJJOV-JOCHJYFZSA-N 0.000 description 1
• NYZZPMVVVGEHQM-AREMUKBSSA-N (2r)-1-[2-[3-[[2-(4-chloro-3-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]-2,3-dihydroindole-2-carboxylic acid Chemical compound N=1C(COC=2C=C(C=CC=2)C(C)(C)C(=O)N2C3=CC=CC=C3C[C@@H]2C(O)=O)=C(C)OC=1C1=CC=C(Cl)C(F)=C1 NYZZPMVVVGEHQM-AREMUKBSSA-N 0.000 description 1
• HPMIIRRRPQSYSS-JOCHJYFZSA-N (2r)-1-[2-[3-[[2-(4-chloro-3-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC=1OC(C=2C=C(F)C(Cl)=CC=2)=NC=1COC(C=1)=CC=CC=1C(C)(C)C(=O)N1CCC[C@@H]1C(O)=O HPMIIRRRPQSYSS-JOCHJYFZSA-N 0.000 description 1
• VZHSVWPBQJLEAE-AREMUKBSSA-N (2r)-1-[2-[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]-2,3-dihydroindole-2-carboxylic acid Chemical compound N=1C(COC=2C=C(C=CC=2)C(C)(C)C(=O)N2C3=CC=CC=C3C[C@@H]2C(O)=O)=C(C)OC=1C1=CC=C(Cl)C=C1 VZHSVWPBQJLEAE-AREMUKBSSA-N 0.000 description 1
• HZOPLJHDBHXQFB-JOCHJYFZSA-N (2r)-1-[2-[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC=1OC(C=2C=CC(Cl)=CC=2)=NC=1COC(C=1)=CC=CC=1C(C)(C)C(=O)N1CCC[C@@H]1C(O)=O HZOPLJHDBHXQFB-JOCHJYFZSA-N 0.000 description 1
• FBAOIPOOEGBIOR-HHHXNRCGSA-N (2r)-1-[2-[3-[[2-(4-cyanophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]-2,3-dihydroindole-2-carboxylic acid Chemical compound N=1C(COC=2C=C(C=CC=2)C(C)(C)C(=O)N2C3=CC=CC=C3C[C@@H]2C(O)=O)=C(C)OC=1C1=CC=C(C#N)C=C1 FBAOIPOOEGBIOR-HHHXNRCGSA-N 0.000 description 1
• IVAHRRWHSCYTKB-HSZRJFAPSA-N (2r)-1-[2-[3-[[2-(4-cyanophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC=1OC(C=2C=CC(=CC=2)C#N)=NC=1COC(C=1)=CC=CC=1C(C)(C)C(=O)N1CCC[C@@H]1C(O)=O IVAHRRWHSCYTKB-HSZRJFAPSA-N 0.000 description 1
• UNJKUDHNRSIVLS-RUZDIDTESA-N (2r)-1-[2-[3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]-4-methoxyphenyl]-2-methylpropanoyl]-2,3-dihydroindole-2-carboxylic acid Chemical compound COC1=CC=C(C(C)(C)C(=O)N2C3=CC=CC=C3C[C@@H]2C(O)=O)C=C1OCC(=C(O1)C)N=C1C1=CC=C(F)C=C1 UNJKUDHNRSIVLS-RUZDIDTESA-N 0.000 description 1
• XKBQCWYTDXNJGX-OAQYLSRUSA-N (2r)-1-[2-[3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]-4-methoxyphenyl]-2-methylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound COC1=CC=C(C(C)(C)C(=O)N2[C@H](CCC2)C(O)=O)C=C1OCC(=C(O1)C)N=C1C1=CC=C(F)C=C1 XKBQCWYTDXNJGX-OAQYLSRUSA-N 0.000 description 1
• ORICCQQBSKUZDI-AREMUKBSSA-N (2r)-1-[2-[3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]-2,3-dihydroindole-2-carboxylic acid Chemical compound N=1C(COC=2C=C(C=CC=2)C(C)(C)C(=O)N2C3=CC=CC=C3C[C@@H]2C(O)=O)=C(C)OC=1C1=CC=C(F)C=C1 ORICCQQBSKUZDI-AREMUKBSSA-N 0.000 description 1
• MCBDFKKRYBVIAV-JOCHJYFZSA-N (2r)-1-[2-[3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC=1OC(C=2C=CC(F)=CC=2)=NC=1COC(C=1)=CC=CC=1C(C)(C)C(=O)N1CCC[C@@H]1C(O)=O MCBDFKKRYBVIAV-JOCHJYFZSA-N 0.000 description 1
• VOXYTQKHZLARFZ-OAQYLSRUSA-N (2r)-1-[2-[3-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]phenyl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound CC=1OC(C=2C=CC(=CC=2)C(F)(F)F)=NC=1COC(C=1)=CC=CC=1CC(=O)N1CCC[C@@H]1C(O)=O VOXYTQKHZLARFZ-OAQYLSRUSA-N 0.000 description 1
• LHKUDGVXMSLLQQ-HXUWFJFHSA-N (2r)-1-[2-[4-[2-[[2-[4-(trifluoromethyl)phenyl]acetyl]amino]ethyl]phenyl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@H]1CCCN1C(=O)CC(C=C1)=CC=C1CCNC(=O)CC1=CC=C(C(F)(F)F)C=C1 LHKUDGVXMSLLQQ-HXUWFJFHSA-N 0.000 description 1
• SKLDOOHBLSVNHL-AREMUKBSSA-N (2r)-1-[2-methyl-2-[3-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]propanoyl]-2,3-dihydroindole-2-carboxylic acid Chemical compound N=1C(COC=2C=C(C=CC=2)C(C)(C)C(=O)N2C3=CC=CC=C3C[C@@H]2C(O)=O)=C(C)OC=1C1=CC=CC=C1 SKLDOOHBLSVNHL-AREMUKBSSA-N 0.000 description 1
• XRWIDXUNUCQCLH-JOCHJYFZSA-N (2r)-1-[2-methyl-2-[3-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]propanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1COC(C=1)=CC=CC=1C(C)(C)C(=O)N1CCC[C@@H]1C(O)=O XRWIDXUNUCQCLH-JOCHJYFZSA-N 0.000 description 1
• DDVWZEIFDARXDX-OAQYLSRUSA-N (2r)-1-[2-methyl-2-[3-[[(4-methyl-2-phenyl-1,3-thiazole-5-carbonyl)amino]methyl]phenyl]propanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC=1N=C(C=2C=CC=CC=2)SC=1C(=O)NCC(C=1)=CC=CC=1C(C)(C)C(=O)N1CCC[C@@H]1C(O)=O DDVWZEIFDARXDX-OAQYLSRUSA-N 0.000 description 1
• RJLOQKMLBMYODY-HHHXNRCGSA-N (2r)-1-[2-methyl-2-[3-[[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]methoxy]phenyl]propanoyl]-2,3-dihydroindole-2-carboxylic acid Chemical compound N=1C(COC=2C=C(C=CC=2)C(C)(C)C(=O)N2C3=CC=CC=C3C[C@@H]2C(O)=O)=C(C)OC=1C1=CC=C(C)C=C1 RJLOQKMLBMYODY-HHHXNRCGSA-N 0.000 description 1
• KJBNRDVHDGYSQJ-HSZRJFAPSA-N (2r)-1-[2-methyl-2-[3-[[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]methoxy]phenyl]propanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC=1OC(C=2C=CC(C)=CC=2)=NC=1COC(C=1)=CC=CC=1C(C)(C)C(=O)N1CCC[C@@H]1C(O)=O KJBNRDVHDGYSQJ-HSZRJFAPSA-N 0.000 description 1
• WMYISXAAFAQGLA-AREMUKBSSA-N (2r)-1-[2-methyl-2-[3-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]phenyl]propanoyl]-2,3-dihydroindole-2-carboxylic acid Chemical compound N=1C(COC=2C=C(C=CC=2)C(C)(C)C(=O)N2C3=CC=CC=C3C[C@@H]2C(O)=O)=C(C)OC=1C1=CC=C(C(F)(F)F)C=C1 WMYISXAAFAQGLA-AREMUKBSSA-N 0.000 description 1
• JJFMDFFHNMQHCX-JOCHJYFZSA-N (2r)-1-[2-methyl-2-[3-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]phenyl]propanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC=1OC(C=2C=CC(=CC=2)C(F)(F)F)=NC=1COC(C=1)=CC=CC=1C(C)(C)C(=O)N1CCC[C@@H]1C(O)=O JJFMDFFHNMQHCX-JOCHJYFZSA-N 0.000 description 1
• UFZPEFSLMLQXBV-OAQYLSRUSA-N (2r)-1-[2-methyl-2-[4-[[methyl-[2-[4-(trifluoromethyl)phenyl]acetyl]amino]methyl]phenyl]propanoyl]pyrrolidine-2-carboxylic acid Chemical compound C=1C=C(C(F)(F)F)C=CC=1CC(=O)N(C)CC(C=C1)=CC=C1C(C)(C)C(=O)N1CCC[C@@H]1C(O)=O UFZPEFSLMLQXBV-OAQYLSRUSA-N 0.000 description 1
• VFDNGGQNCUMVBH-HXUWFJFHSA-N (2r)-1-[3-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenoxy]carbonylpyrrolidine-2-carboxylic acid Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1COC(C=1)=CC=CC=1OC(=O)N1CCC[C@@H]1C(O)=O VFDNGGQNCUMVBH-HXUWFJFHSA-N 0.000 description 1
• NSQQCEJNBOAAGP-HXUWFJFHSA-N (2r)-1-[3-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]sulfanylcarbonylpyrrolidine-2-carboxylic acid Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1COC(C=1)=CC=CC=1SC(=O)N1CCC[C@@H]1C(O)=O NSQQCEJNBOAAGP-HXUWFJFHSA-N 0.000 description 1
• KVVODNUBDFULSC-XMMPIXPASA-N (2r)-1-[4-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]phenyl]sulfonyl-2,3-dihydroindole-2-carboxylic acid Chemical compound N=1C(COC=2C=CC(=CC=2)S(=O)(=O)N2C3=CC=CC=C3C[C@@H]2C(O)=O)=C(C)OC=1C1=CC=C(C(F)(F)F)C=C1 KVVODNUBDFULSC-XMMPIXPASA-N 0.000 description 1
• GKSZYJFJGGPJEY-NRFANRHFSA-N (2s)-1-[2-[3-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1COC(C=1)=CC=CC=1CC(=O)N1CCC[C@H]1C(O)=O GKSZYJFJGGPJEY-NRFANRHFSA-N 0.000 description 1
• BLWKWOVOFWHFLD-FQEVSTJZSA-N (2s)-2-(2-benzoylanilino)-3-(4-hydroxyphenyl)propanoic acid Chemical class C([C@@H](C(=O)O)NC=1C(=CC=CC=1)C(=O)C=1C=CC=CC=1)C1=CC=C(O)C=C1 BLWKWOVOFWHFLD-FQEVSTJZSA-N 0.000 description 1
• KDQWIKMBLSWIPD-ABLWVSNPSA-N (2s)-2-[(2-benzyl-3-sulfanylpropanoyl)amino]-4,4-bis(methylsulfanyl)butanoic acid Chemical compound CSC(SC)C[C@@H](C(O)=O)NC(=O)C(CS)CC1=CC=CC=C1 KDQWIKMBLSWIPD-ABLWVSNPSA-N 0.000 description 1
• QAQRHURCJWHRJU-FHWLQOOXSA-N (2s)-2-[[(2s)-1-[[(2s)-2-carboxy-2-hydroxyethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-phenylbutanoic acid Chemical compound C([C@@H](C(=O)NC[C@H](O)C(O)=O)N[C@@H](CCC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 QAQRHURCJWHRJU-FHWLQOOXSA-N 0.000 description 1
• FGXXIAHRYGHABD-KGLIPLIRSA-N (2s)-2-[[(2s)-2-[(2-methylphenyl)methyl]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](CS)CC1=CC=CC=C1C FGXXIAHRYGHABD-KGLIPLIRSA-N 0.000 description 1
• FGXXIAHRYGHABD-KZUDCZAMSA-N (2s)-2-[[2-[(2-methylphenyl)methyl]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound CSCC[C@@H](C(O)=O)NC(=O)C(CS)CC1=CC=CC=C1C FGXXIAHRYGHABD-KZUDCZAMSA-N 0.000 description 1
• PQSUQDFBGSIHKA-NEPJUHHUSA-N (2s)-2-hydroxy-3-[[(2s)-2-[(2-methylphenyl)methyl]-3-sulfanylpropanoyl]amino]propanoic acid Chemical compound CC1=CC=CC=C1C[C@H](CS)C(=O)NC[C@H](O)C(O)=O PQSUQDFBGSIHKA-NEPJUHHUSA-N 0.000 description 1
• IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
• 125000006655 (C3-C8) heteroaryl group Chemical group 0.000 description 1
• METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
• TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
• ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
• CPHOHOZBKYXBOE-UHFFFAOYSA-N 1,5,6-triphenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C=1C=CC=CC=1C1=NC=2N(C=3C=CC=CC=3)N=CC=2C(=O)N1C1=CC=CC=C1 CPHOHOZBKYXBOE-UHFFFAOYSA-N 0.000 description 1
• MPULOWQWEXSORW-UHFFFAOYSA-N 1,6-diphenyl-5-(4-propan-2-ylphenyl)pyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(C(C)C)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=CC=C1 MPULOWQWEXSORW-UHFFFAOYSA-N 0.000 description 1
• TZESSPPAPLHFEQ-UHFFFAOYSA-N 2-[(2-benzyl-3-sulfanylpropanoyl)amino]-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC(NC(=O)C(CS)CC=2C=CC=CC=2)=N1 TZESSPPAPLHFEQ-UHFFFAOYSA-N 0.000 description 1
• XMQODGUTLZXUGZ-RPBOFIJWSA-N 2-[(3s)-3-[[1-[(2r)-2-ethoxycarbonyl-4-phenylbutyl]cyclopentanecarbonyl]amino]-2-oxo-4,5-dihydro-3h-1-benzazepin-1-yl]acetic acid Chemical compound C([C@@H](C(=O)OCC)CC1(CCCC1)C(=O)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XMQODGUTLZXUGZ-RPBOFIJWSA-N 0.000 description 1
• OSJSRBCOQRHXEC-LYKKTTPLSA-N 2-[[1-[[(2s)-2-carboxy-2-hydroxyethyl]carbamoyl]cyclopentyl]methyl]-4-phenylbutanoic acid Chemical compound C=1C=CC=CC=1CCC(C(O)=O)CC1(C(=O)NC[C@H](O)C(O)=O)CCCC1 OSJSRBCOQRHXEC-LYKKTTPLSA-N 0.000 description 1
• SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
• YZQLWPMZQVHJED-UHFFFAOYSA-N 2-methylpropanethioic acid S-[2-[[[1-(2-ethylbutyl)cyclohexyl]-oxomethyl]amino]phenyl] ester Chemical compound C=1C=CC=C(SC(=O)C(C)C)C=1NC(=O)C1(CC(CC)CC)CCCCC1 YZQLWPMZQVHJED-UHFFFAOYSA-N 0.000 description 1
• NMKSAYKQLCHXDK-UHFFFAOYSA-N 3,3-diphenyl-N-(1-phenylethyl)-1-propanamine Chemical compound C=1C=CC=CC=1C(C)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 NMKSAYKQLCHXDK-UHFFFAOYSA-N 0.000 description 1
• SUKNXYMRQLQQMI-UHFFFAOYSA-N 3-[(2-benzyl-3-sulfanylpropanoyl)amino]benzoic acid Chemical compound OC(=O)C1=CC=CC(NC(=O)C(CS)CC=2C=CC=CC=2)=C1 SUKNXYMRQLQQMI-UHFFFAOYSA-N 0.000 description 1
• UXTJLCWDHLUAQF-UHFFFAOYSA-N 3-[[2-(acetylsulfanylmethyl)-3-phenylpropanoyl]amino]benzoic acid Chemical compound C=1C=CC(C(O)=O)=CC=1NC(=O)C(CSC(=O)C)CC1=CC=CC=C1 UXTJLCWDHLUAQF-UHFFFAOYSA-N 0.000 description 1
• REPVVNYZORKKPQ-UHFFFAOYSA-N 3-oxo-3-[(1-phenyl-3-sulfanylpropan-2-yl)amino]propanoic acid Chemical compound OC(=O)CC(=O)NC(CS)CC1=CC=CC=C1 REPVVNYZORKKPQ-UHFFFAOYSA-N 0.000 description 1
• NCSNXXXLRVRXIM-UHFFFAOYSA-N 4-[(2-benzyl-3-sulfanylpropanoyl)amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC(=O)C(CS)CC1=CC=CC=C1 NCSNXXXLRVRXIM-UHFFFAOYSA-N 0.000 description 1
• VCFGVPMALWRCTK-UHFFFAOYSA-N 4-[(2-benzyl-3-sulfanylpropanoyl)amino]thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC(NC(=O)C(CS)CC=2C=CC=CC=2)=C1 VCFGVPMALWRCTK-UHFFFAOYSA-N 0.000 description 1
• QBQLYIISSRXYKL-UHFFFAOYSA-N 4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,2-oxazolidine-3,5-dione Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCOC(C=C1)=CC=C1CC1C(=O)NOC1=O QBQLYIISSRXYKL-UHFFFAOYSA-N 0.000 description 1
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
• 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
• MJHKIDXPBNVAGM-UHFFFAOYSA-N 5,6-bis(3-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC=CC(C=2N(C(=O)C=3C=NN(C=3N=2)C=2C=CC=CC=2)C=2C=C(C)C=CC=2)=C1 MJHKIDXPBNVAGM-UHFFFAOYSA-N 0.000 description 1
• GDHPGXMZIAFXCN-UHFFFAOYSA-N 5,6-bis(4-bromophenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(Br)=CC=C1C(N(C1=O)C=2C=CC(Br)=CC=2)=NC2=C1C=NN2C1=CC=CC=C1 GDHPGXMZIAFXCN-UHFFFAOYSA-N 0.000 description 1
• IIQWUHIWAXFABY-UHFFFAOYSA-N 5,6-bis(4-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(C)=CC=C1C(N(C1=O)C=2C=CC(C)=CC=2)=NC2=C1C=NN2C1=CC=CC=C1 IIQWUHIWAXFABY-UHFFFAOYSA-N 0.000 description 1
• BUSHPLPJLFMRIS-UHFFFAOYSA-N 5-(2-methylphenyl)-1,6-diphenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=CC=C1 BUSHPLPJLFMRIS-UHFFFAOYSA-N 0.000 description 1
• CWRJPIDSWJRJIT-UHFFFAOYSA-N 5-(3-chlorophenyl)-6-(2-fluorophenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound FC1=CC=CC=C1C(N(C1=O)C=2C=C(Cl)C=CC=2)=NC2=C1C=NN2C1=CC=CC=C1 CWRJPIDSWJRJIT-UHFFFAOYSA-N 0.000 description 1
• JPYRSEZMZFVLTC-UHFFFAOYSA-N 5-(3-chlorophenyl)-6-(2-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC=CC=C1C(N(C1=O)C=2C=C(Cl)C=CC=2)=NC2=C1C=NN2C1=CC=CC=C1 JPYRSEZMZFVLTC-UHFFFAOYSA-N 0.000 description 1
• AROPKPIERSUSNA-UHFFFAOYSA-N 5-(3-chlorophenyl)-6-(3-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC=CC(C=2N(C(=O)C=3C=NN(C=3N=2)C=2C=CC=CC=2)C=2C=C(Cl)C=CC=2)=C1 AROPKPIERSUSNA-UHFFFAOYSA-N 0.000 description 1
• YWXLLWNVTQDKIP-UHFFFAOYSA-N 5-(3-methylphenyl)-1,6-diphenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC=CC(N2C(C=3C=NN(C=3N=C2C=2C=CC=CC=2)C=2C=CC=CC=2)=O)=C1 YWXLLWNVTQDKIP-UHFFFAOYSA-N 0.000 description 1
• SALFRPOHLBLOIS-UHFFFAOYSA-N 5-(3-methylphenyl)-6-(4-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(C)=CC=C1C(N(C1=O)C=2C=C(C)C=CC=2)=NC2=C1C=NN2C1=CC=CC=C1 SALFRPOHLBLOIS-UHFFFAOYSA-N 0.000 description 1
• JMEWNABJMKGPPW-UHFFFAOYSA-N 5-(4-bromophenyl)-1,6-diphenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(Br)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=CC=C1 JMEWNABJMKGPPW-UHFFFAOYSA-N 0.000 description 1
• AENVNGDHIIEYHT-UHFFFAOYSA-N 5-(4-bromophenyl)-6-(2-fluorophenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound FC1=CC=CC=C1C(N(C1=O)C=2C=CC(Br)=CC=2)=NC2=C1C=NN2C1=CC=CC=C1 AENVNGDHIIEYHT-UHFFFAOYSA-N 0.000 description 1
• MNJDBHHGQPLUDS-UHFFFAOYSA-N 5-(4-bromophenyl)-6-(3-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC=CC(C=2N(C(=O)C=3C=NN(C=3N=2)C=2C=CC=CC=2)C=2C=CC(Br)=CC=2)=C1 MNJDBHHGQPLUDS-UHFFFAOYSA-N 0.000 description 1
• KCSXPQZNRWZJTJ-UHFFFAOYSA-N 5-(4-bromophenyl)-6-(4-chlorophenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(Cl)=CC=C1C(N(C1=O)C=2C=CC(Br)=CC=2)=NC2=C1C=NN2C1=CC=CC=C1 KCSXPQZNRWZJTJ-UHFFFAOYSA-N 0.000 description 1
• VRXFDXJDRFCQEU-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(3-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC=CC(C=2N(C(=O)C=3C=NN(C=3N=2)C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 VRXFDXJDRFCQEU-UHFFFAOYSA-N 0.000 description 1
• RLLFOGZEYMBDAC-UHFFFAOYSA-N 5-(4-ethoxyphenyl)-1,6-diphenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(OCC)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=CC=C1 RLLFOGZEYMBDAC-UHFFFAOYSA-N 0.000 description 1
• OBKCCUHDEJMTCI-UHFFFAOYSA-N 5-(4-ethoxyphenyl)-6-(4-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(OCC)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=C(C)C=C1 OBKCCUHDEJMTCI-UHFFFAOYSA-N 0.000 description 1
• HQBCTHNFYGFTAV-UHFFFAOYSA-N 5-(4-fluorophenyl)-6-(2-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC=CC=C1C(N(C1=O)C=2C=CC(F)=CC=2)=NC2=C1C=NN2C1=CC=CC=C1 HQBCTHNFYGFTAV-UHFFFAOYSA-N 0.000 description 1
• ALCGTUDMLRZXKN-UHFFFAOYSA-N 5-(4-fluorophenyl)-6-(3-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC=CC(C=2N(C(=O)C=3C=NN(C=3N=2)C=2C=CC=CC=2)C=2C=CC(F)=CC=2)=C1 ALCGTUDMLRZXKN-UHFFFAOYSA-N 0.000 description 1
• ZSQUVPGLHAWOPI-UHFFFAOYSA-N 5-(4-methoxyphenyl)-1,6-diphenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=CC=C1 ZSQUVPGLHAWOPI-UHFFFAOYSA-N 0.000 description 1
• XGJYMGFLZJCJHO-UHFFFAOYSA-N 5-(4-methoxyphenyl)-6-(4-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=C(C)C=C1 XGJYMGFLZJCJHO-UHFFFAOYSA-N 0.000 description 1
• WGPDUTXOBVXSRI-UHFFFAOYSA-N 5-(4-methylphenyl)-1,6-diphenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(C)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=CC=C1 WGPDUTXOBVXSRI-UHFFFAOYSA-N 0.000 description 1
• GWZJXMRSPIFFAK-UHFFFAOYSA-N 5-[(2-naphthalen-2-yl-1,3-benzoxazol-5-yl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(OC(=N2)C=3C=C4C=CC=CC4=CC=3)C2=C1 GWZJXMRSPIFFAK-UHFFFAOYSA-N 0.000 description 1
• MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 description 1
• PCAZCAZVHLGDBA-UHFFFAOYSA-N 5-[[4-(2-indol-1-ylethoxy)phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC(C=C1)=CC=C1OCCN1C2=CC=CC=C2C=C1 PCAZCAZVHLGDBA-UHFFFAOYSA-N 0.000 description 1
• WWGVNZWSVJDZLH-UHFFFAOYSA-N 5-[[4-[2-(2,3-dihydroindol-1-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC(C=C1)=CC=C1OCCN1C2=CC=CC=C2CC1 WWGVNZWSVJDZLH-UHFFFAOYSA-N 0.000 description 1
• YVQKIDLSVHRBGZ-UHFFFAOYSA-N 5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1C(O)COC(C=C1)=CC=C1CC1SC(=O)NC1=O YVQKIDLSVHRBGZ-UHFFFAOYSA-N 0.000 description 1
• RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
• JEZSDRHESDMHBO-UHFFFAOYSA-N 6-(2-fluorophenyl)-1,5-diphenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound FC1=CC=CC=C1C(N(C1=O)C=2C=CC=CC=2)=NC2=C1C=NN2C1=CC=CC=C1 JEZSDRHESDMHBO-UHFFFAOYSA-N 0.000 description 1
• BUKRCICRNQXJCV-UHFFFAOYSA-N 6-(2-fluorophenyl)-5-(2-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=CC=C1F BUKRCICRNQXJCV-UHFFFAOYSA-N 0.000 description 1
• ISKBCNMOTUDCIK-UHFFFAOYSA-N 6-(2-fluorophenyl)-5-(4-fluorophenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=CC=C1F ISKBCNMOTUDCIK-UHFFFAOYSA-N 0.000 description 1
• XRARRQSWWSOIRH-UHFFFAOYSA-N 6-(2-fluorophenyl)-5-(4-methoxyphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=CC=C1F XRARRQSWWSOIRH-UHFFFAOYSA-N 0.000 description 1
• VOFVABHNXPTPSK-UHFFFAOYSA-N 6-(2-fluorophenyl)-5-(4-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(C)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=CC=C1F VOFVABHNXPTPSK-UHFFFAOYSA-N 0.000 description 1
• ABDXHFUCCHDUCQ-UHFFFAOYSA-N 6-(2-methylphenyl)-5-(4-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(C)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=CC=C1C ABDXHFUCCHDUCQ-UHFFFAOYSA-N 0.000 description 1
• UVALKLHAOVESBN-UHFFFAOYSA-N 6-(3-methylphenyl)-1,5-diphenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC=CC(C=2N(C(=O)C=3C=NN(C=3N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 UVALKLHAOVESBN-UHFFFAOYSA-N 0.000 description 1
• SIOYQFGOQWFIAP-UHFFFAOYSA-N 6-(3-methylphenyl)-1-phenyl-5-(4-propan-2-ylphenyl)pyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(C(C)C)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=CC(C)=C1 SIOYQFGOQWFIAP-UHFFFAOYSA-N 0.000 description 1
• DVUGYDCGGNOGIV-UHFFFAOYSA-N 6-(3-methylphenyl)-5-(4-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(C)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=CC(C)=C1 DVUGYDCGGNOGIV-UHFFFAOYSA-N 0.000 description 1
• MYYLELYEUPMFPZ-UHFFFAOYSA-N 6-(4-bromophenyl)-1-phenyl-5-(4-propan-2-ylphenyl)pyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(C(C)C)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=C(Br)C=C1 MYYLELYEUPMFPZ-UHFFFAOYSA-N 0.000 description 1
• LLWGEJHKYINBQU-UHFFFAOYSA-N 6-(4-bromophenyl)-5-(4-chlorophenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(Cl)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=C(Br)C=C1 LLWGEJHKYINBQU-UHFFFAOYSA-N 0.000 description 1
• AGQPWOSMZZJEJK-UHFFFAOYSA-N 6-(4-bromophenyl)-5-(4-ethoxyphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(OCC)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=C(Br)C=C1 AGQPWOSMZZJEJK-UHFFFAOYSA-N 0.000 description 1
• MMEHYYYPJXTOED-UHFFFAOYSA-N 6-(4-bromophenyl)-5-(4-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(C)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=C(Br)C=C1 MMEHYYYPJXTOED-UHFFFAOYSA-N 0.000 description 1
• NVLXAGRSNYTNGV-UHFFFAOYSA-N 6-(4-chlorophenyl)-5-(2-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=C(Cl)C=C1 NVLXAGRSNYTNGV-UHFFFAOYSA-N 0.000 description 1
• BYDDPXHDRAOTMO-UHFFFAOYSA-N 6-(4-chlorophenyl)-5-(3-methylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound CC1=CC=CC(N2C(C=3C=NN(C=3N=C2C=2C=CC(Cl)=CC=2)C=2C=CC=CC=2)=O)=C1 BYDDPXHDRAOTMO-UHFFFAOYSA-N 0.000 description 1
• XCDRNJXUUVWVMT-UHFFFAOYSA-N 6-(4-chlorophenyl)-5-(4-ethoxyphenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(OCC)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=C(Cl)C=C1 XCDRNJXUUVWVMT-UHFFFAOYSA-N 0.000 description 1
• FCYUOLKDUVVDJS-UHFFFAOYSA-N 6-(4-chlorophenyl)-5-(4-fluorophenyl)-1-phenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=C(Cl)C=C1 FCYUOLKDUVVDJS-UHFFFAOYSA-N 0.000 description 1
• POYSPKBDRLZYEA-UHFFFAOYSA-N 6-(4-methylphenyl)-1,5-diphenylpyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(C)=CC=C1C(N(C1=O)C=2C=CC=CC=2)=NC2=C1C=NN2C1=CC=CC=C1 POYSPKBDRLZYEA-UHFFFAOYSA-N 0.000 description 1
• ZJMFIEXPQMBOLU-UHFFFAOYSA-N 6-(4-methylphenyl)-1-phenyl-5-(4-propan-2-ylphenyl)pyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=CC(C(C)C)=CC=C1N1C(=O)C(C=NN2C=3C=CC=CC=3)=C2N=C1C1=CC=C(C)C=C1 ZJMFIEXPQMBOLU-UHFFFAOYSA-N 0.000 description 1
• KJVKOEVEFLXJES-UHFFFAOYSA-N 7-[(2-benzyl-3-sulfanylpropanoyl)amino]heptanoic acid Chemical compound OC(=O)CCCCCCNC(=O)C(CS)CC1=CC=CC=C1 KJVKOEVEFLXJES-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
• UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 description 1
• 206010002383 Angina Pectoris Diseases 0.000 description 1
• 102400000344 Angiotensin-1 Human genes 0.000 description 1
• 101800000734 Angiotensin-1 Proteins 0.000 description 1
• 102400000345 Angiotensin-2 Human genes 0.000 description 1
• 101800000733 Angiotensin-2 Proteins 0.000 description 1
• 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
• BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
• 229940122815 Aromatase inhibitor Drugs 0.000 description 1
• 206010003497 Asphyxia Diseases 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
• LDOFBCFBEJQIIY-PKHIMPSTSA-N C(C)(=O)SCC(C(=O)[C@@]1(C(=O)NCCCC1)N)CC1=CC=CC=C1 Chemical compound C(C)(=O)SCC(C(=O)[C@@]1(C(=O)NCCCC1)N)CC1=CC=CC=C1 LDOFBCFBEJQIIY-PKHIMPSTSA-N 0.000 description 1
• 239000002083 C09CA01 - Losartan Substances 0.000 description 1
• 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
• 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
• 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
• 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
• 101150062316 CHRNA2 gene Proteins 0.000 description 1
• 229940122820 Cannabinoid receptor antagonist Drugs 0.000 description 1
• 108010009685 Cholinergic Receptors Proteins 0.000 description 1
• 108010064945 D-4F peptide Proteins 0.000 description 1
• QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• 229940122783 Endothelin converting-enzyme inhibitor Drugs 0.000 description 1
• HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
• 208000036993 Frustration Diseases 0.000 description 1
• 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
• 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical class NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
• 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
• CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
• 102000003746 Insulin Receptor Human genes 0.000 description 1
• 108010001127 Insulin Receptor Proteins 0.000 description 1
• 229930195722 L-methionine Natural products 0.000 description 1
• 108010007859 Lisinopril Proteins 0.000 description 1
• CESYKOGBSMNBPD-UHFFFAOYSA-N Methyclothiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CCl)NC2=C1 CESYKOGBSMNBPD-UHFFFAOYSA-N 0.000 description 1
• HBNPJJILLOYFJU-VMPREFPWSA-N Mibefradil Chemical compound C1CC2=CC(F)=CC=C2[C@H](C(C)C)[C@@]1(OC(=O)COC)CCN(C)CCCC1=NC2=CC=CC=C2N1 HBNPJJILLOYFJU-VMPREFPWSA-N 0.000 description 1
• 150000001204 N-oxides Chemical class 0.000 description 1
• FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 239000005480 Olmesartan Substances 0.000 description 1
• 208000031481 Pathologic Constriction Diseases 0.000 description 1
• ZPHBZEQOLSRPAK-UHFFFAOYSA-N Phosphoramidon Natural products C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O ZPHBZEQOLSRPAK-UHFFFAOYSA-N 0.000 description 1
• 102100040918 Pro-glucagon Human genes 0.000 description 1
• 206010042957 Systolic hypertension Diseases 0.000 description 1
• 108010036928 Thiorphan Proteins 0.000 description 1
• VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
• FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
• UWAOJIWUVCMBAZ-UHFFFAOYSA-N [1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-dimethylazanium;chloride Chemical compound Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UWAOJIWUVCMBAZ-UHFFFAOYSA-N 0.000 description 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
• 229960002122 acebutolol Drugs 0.000 description 1
• GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
• 102000034337 acetylcholine receptors Human genes 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 238000010306 acid treatment Methods 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
• 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
• 229960002576 amiloride Drugs 0.000 description 1
• XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
• 229940024606 amino acid Drugs 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 229960002932 anastrozole Drugs 0.000 description 1
• YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
• ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
• 229950006323 angiotensin ii Drugs 0.000 description 1
• 230000008485 antagonism Effects 0.000 description 1
• 239000004004 anti-anginal agent Substances 0.000 description 1
• 230000003579 anti-obesity Effects 0.000 description 1
• 239000003416 antiarrhythmic agent Substances 0.000 description 1
• 229940046844 aromatase inhibitors Drugs 0.000 description 1
• 229960002274 atenolol Drugs 0.000 description 1
• 229960004067 benazeprilat Drugs 0.000 description 1
• MADRIHWFJGRSBP-ROUUACIJSA-N benazeprilat Chemical compound C([C@H](N[C@H]1CCC2=CC=CC=C2N(C1=O)CC(=O)O)C(O)=O)CC1=CC=CC=C1 MADRIHWFJGRSBP-ROUUACIJSA-N 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• 229960004324 betaxolol Drugs 0.000 description 1
• CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
• 235000010290 biphenyl Nutrition 0.000 description 1
• 229960002781 bisoprolol Drugs 0.000 description 1
• VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 230000036772 blood pressure Effects 0.000 description 1
• 229960000932 candesartan Drugs 0.000 description 1
• SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
• 239000003536 cannabinoid receptor antagonist Substances 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 125000002843 carboxylic acid group Chemical group 0.000 description 1
• FYBXRCFPOTXTJF-UHFFFAOYSA-N carteolol hydrochloride Chemical compound [Cl-].N1C(=O)CCC2=C1C=CC=C2OCC(O)C[NH2+]C(C)(C)C FYBXRCFPOTXTJF-UHFFFAOYSA-N 0.000 description 1
• 229960004195 carvedilol Drugs 0.000 description 1
• NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
• JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
• 239000003795 chemical substances by application Substances 0.000 description 1
• 125000000068 chlorophenyl group Chemical group 0.000 description 1
• 229960002155 chlorothiazide Drugs 0.000 description 1
• 208000020832 chronic kidney disease Diseases 0.000 description 1
• 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
• YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
• 229950009226 ciglitazone Drugs 0.000 description 1
• 229960005025 cilazapril Drugs 0.000 description 1
• HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
• 229960003009 clopidogrel Drugs 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 230000002301 combined effect Effects 0.000 description 1
• 235000019788 craving Nutrition 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 125000006638 cyclopentyl carbonyl group Chemical group 0.000 description 1
• 235000021316 daily nutritional intake Nutrition 0.000 description 1
• QQKNSPHAFATFNQ-UHFFFAOYSA-N darglitazone Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCC(=O)C(C=C1)=CC=C1CC1SC(=O)NC1=O QQKNSPHAFATFNQ-UHFFFAOYSA-N 0.000 description 1
• 229960005227 delapril Drugs 0.000 description 1
• WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 1
• 208000033679 diabetic kidney disease Diseases 0.000 description 1
• 210000001198 duodenum Anatomy 0.000 description 1
• 230000001258 dyslipidemic effect Effects 0.000 description 1
• 230000002888 effect on disease Effects 0.000 description 1
• 239000002857 endothelin converting enzyme inhibitor Substances 0.000 description 1
• 229950002375 englitazone Drugs 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 239000002792 enkephalinase inhibitor Substances 0.000 description 1
• 230000007515 enzymatic degradation Effects 0.000 description 1
• 229960004563 eprosartan Drugs 0.000 description 1
• OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
• 229960003745 esmolol Drugs 0.000 description 1
• AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 229960000255 exemestane Drugs 0.000 description 1
• 229960003580 felodipine Drugs 0.000 description 1
• 229960002602 fendiline Drugs 0.000 description 1
• SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 1
• 229960000326 flunarizine Drugs 0.000 description 1
• 238000005755 formation reaction Methods 0.000 description 1
• 235000021588 free fatty acids Nutrition 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 230000004153 glucose metabolism Effects 0.000 description 1
• 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
• 201000008980 hyperinsulinism Diseases 0.000 description 1
• 229960001195 imidapril Drugs 0.000 description 1
• KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 229960002198 irbesartan Drugs 0.000 description 1
• YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 229960001632 labetalol Drugs 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 229960002394 lisinopril Drugs 0.000 description 1
• RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
• 229960004773 losartan Drugs 0.000 description 1
• KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 229940045623 meridia Drugs 0.000 description 1
• VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
• YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
• 229960004438 mibefradil Drugs 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
• 229960004255 nadolol Drugs 0.000 description 1
• VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
• PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 229960005366 nilvadipine Drugs 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
• VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 1
• 229960005117 olmesartan Drugs 0.000 description 1
• AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
• 229960004570 oxprenolol Drugs 0.000 description 1
• 229960002035 penbutolol Drugs 0.000 description 1
• KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 1
• 229960005190 phenylalanine Drugs 0.000 description 1
• BWSDNRQVTFZQQD-AYVHNPTNSA-N phosphoramidon Chemical compound O([P@@](O)(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC=1[C]2C=CC=CC2=NC=1)C(O)=O)[C@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]1O BWSDNRQVTFZQQD-AYVHNPTNSA-N 0.000 description 1
• 108010072906 phosphoramidon Proteins 0.000 description 1
• 229960002508 pindolol Drugs 0.000 description 1
• PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 108090000765 processed proteins & peptides Proteins 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 229960001455 quinapril Drugs 0.000 description 1
• JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 108700016891 retrothiorphan Proteins 0.000 description 1
• 230000000250 revascularization Effects 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 239000012439 solid excipient Substances 0.000 description 1
• 229960002370 sotalol Drugs 0.000 description 1
• ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 229960002909 spirapril Drugs 0.000 description 1
• 108700035424 spirapril Proteins 0.000 description 1
• HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 description 1
• 208000037804 stenosis Diseases 0.000 description 1
• 230000036262 stenosis Effects 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 150000003892 tartrate salts Chemical class 0.000 description 1
• 229960005187 telmisartan Drugs 0.000 description 1
• 229960004084 temocapril Drugs 0.000 description 1
• FIQOFIRCTOWDOW-BJLQDIEVSA-N temocapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C[C@H](SC1)C=1SC=CC=1)=O)CC1=CC=CC=C1 FIQOFIRCTOWDOW-BJLQDIEVSA-N 0.000 description 1
• 150000003536 tetrazoles Chemical class 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 239000003451 thiazide diuretic agent Substances 0.000 description 1
• 150000001467 thiazolidinediones Chemical class 0.000 description 1
• LJJKNPQAGWVLDQ-SNVBAGLBSA-N thiorphan Chemical compound OC(=O)CNC(=O)[C@@H](CS)CC1=CC=CC=C1 LJJKNPQAGWVLDQ-SNVBAGLBSA-N 0.000 description 1
• 229960004605 timolol Drugs 0.000 description 1
• 229960002051 trandolapril Drugs 0.000 description 1
• 229960001288 triamterene Drugs 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 1
• 229960004699 valsartan Drugs 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 230000009278 visceral effect Effects 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 229940002552 xenical Drugs 0.000 description 1